{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:06:16Z","timestamp":1794002776120,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>KIR\/HLA mismatch in hematopoietic stem cell transplantation (HSCT), particularly in patients with acute myeloid leukemia (AML), was related to decreased recurrence rates, improved engraftment, and a reduction in graft-versus-host disease, according to recent research (GVHD). Uncertainty exists about the impact of KIR\/HLA mismatch on haploidentical-HSCTs treated with post-transplant cyclophosphamide (PTCy). We attempted to analyze the effects of KIR\/HLA mismatch on clinical outcomes on transplant outcomes using the cohort of 54 AML patients who received a haplo-HSCT with PTCy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In contrast to KIR\/HLA match, our findings showed that donor KIR\/HLA mismatch was substantially associated with superior OS (HR, 2.92; (<jats:italic>P<\/jats:italic>\u2009=\u20090.04)). Moreover, donor KIR\/HLA mismatch (KIR2DS1<jats:sub>D<\/jats:sub>\/C2<jats:sup>+<\/jats:sup><jats:sub>R<\/jats:sub> and KIR2DS2<jats:sub>D<\/jats:sub>\/C1<jats:sup>+<\/jats:sup><jats:sub>R<\/jats:sub> mismatch versus KIR2DL1<jats:sub>D<\/jats:sub>\/C2<jats:sup>\u2212<\/jats:sup><jats:sub>R<\/jats:sub> mm, KIR2DL2\/3<jats:sub>D<\/jats:sub>\/C1<jats:sup>\u2212<\/jats:sup><jats:sub>R<\/jats:sub> mm and KIR3DL1<jats:sub>D<\/jats:sub>\/Bw4<jats:sup>\u2212<\/jats:sup> mm) was correlated with the improvements in OS (HR, 0.74; <jats:italic>P<\/jats:italic>\u2009=\u20090.085) and activating. KIR\/HLA mismatch versus KIR\/HLA match was significantly correlated with improvements in OS (HR, .46; <jats:italic>P<\/jats:italic>\u2009=\u20090.03) and inhibitory. KIR\/HLA mismatch versus KIR\/HLA match was enhancement in the OS (HR, .93; <jats:italic>P<\/jats:italic>\u2009=\u20090.06). Despite a higher rate of aGvHD (grade I-IV) in the patients with KIR\/HLA mismatch compared to KIR\/HLA matched (57% vs. 33% (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). However, the KIR\/HLA mismatch group saw a decreased relapse rate (3.2% vs. 23%, <jats:italic>p<\/jats:italic>\u2009=\u20090.04).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This analysis shows the significance of KIR\/HLA Incompatibility, other clinical variables like CMV, the relationship between donor\/recipient and donor age, and the relationship between donor\/recipient and donor age in the haplo-donor selection process. It also suggests that KIR and HLA mismatching between donor and recipient could be routinely performed for haplo-donor selection and may improve clinical outcomes after haplo-HSCTs with PTCy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12865-023-00548-1","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T17:02:14Z","timestamp":1687280534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Investigation of KIR\/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML)"],"prefix":"10.1186","volume":"24","author":[{"given":"Tahereh","family":"Bakhtiari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Yaghmaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seied Asadollah","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazdak","family":"Ganjalikhani-Hakemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"issue":"4","key":"548_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1056\/NEJM198901263200401","volume":"320","author":"C Anasetti","year":"1989","unstructured":"Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. New Engl J Med. 1989;320(4):197\u2013204.","journal-title":"New Engl J Med"},{"issue":"24","key":"548_CR2","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2018-07-861575","volume":"132","author":"A Bertaina","year":"2018","unstructured":"Bertaina A, Zecca M, Buldini B, Sacchi N, Algeri M, Saglio F, et al. Unrelated donor vs HLA-haploidentical \u03b1\/\u03b2 T-cell\u2013and B-cell\u2013depleted HSCT in children with acute leukemia. Blood. 2018;132(24):2594\u2013607.","journal-title":"Blood"},{"issue":"6","key":"548_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/bmt.2017.34","volume":"52","author":"J Passweg","year":"2017","unstructured":"Passweg J, Baldomero H, Bader P, Bonini C, Duarte R, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52(6):811\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"548_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.758512","volume":"11","author":"YJ Chang","year":"2021","unstructured":"Chang YJ, Zhao XY, Huang XJ. Haploidentical stem cell transplantation for acute myeloid leukemia: current therapies, challenges and future prospective. Front Oncol. 2021;11: 758512.","journal-title":"Front Oncol"},{"issue":"12","key":"548_CR5","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","volume":"133","author":"R Zeiser","year":"2019","unstructured":"Zeiser R, Vago L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood. 2019;133(12):1290\u20137.","journal-title":"Blood"},{"key":"548_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fimmu.2016.00188","volume":"7","author":"P Vacca","year":"2016","unstructured":"Vacca P, et al. NK cells and other innate lymphoid cells in hematopoietic stem cell transplantation. Front Immunol. 2016;7:188.","journal-title":"Front Immunol"},{"issue":"7","key":"548_CR7","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/leu.2009.21","volume":"23","author":"BM Triplett","year":"2009","unstructured":"Triplett BM, et al. Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia. 2009;23(7):1278\u201387.","journal-title":"Leukemia"},{"issue":"11","key":"548_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633\u201340.","journal-title":"Trends Immunol"},{"key":"548_CR9","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","volume":"8","author":"S Paul","year":"2017","unstructured":"Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 2017;8:1124.","journal-title":"Front Immunol"},{"key":"548_CR10","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1084\/jem.169.6.2233","volume":"169","author":"LL Lanier","year":"1989","unstructured":"Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med. 1989;169:2233\u20138.","journal-title":"J Exp Med"},{"issue":"5","key":"548_CR11","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","volume":"174","author":"E Vivier","year":"2018","unstructured":"Vivier E, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174(5):1054\u201366.","journal-title":"Cell"},{"issue":"5","key":"548_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/ni0508-477","volume":"9","author":"K K\u00e4rre","year":"2008","unstructured":"K\u00e4rre K. Natural killer cell recognition of missing self. Nat Immunol. 2008;9(5):477\u201380.","journal-title":"Nat Immunol"},{"key":"548_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","volume":"11","author":"H-G Ljunggren","year":"1990","unstructured":"Ljunggren H-G, K\u00e4rre K. In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition. Immunol Today. 1990;11:237\u201344.","journal-title":"Immunol Today"},{"issue":"3","key":"548_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"548_CR15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1146\/annurev-biochem-011520-102754","volume":"89","author":"Z Djaoud","year":"2020","unstructured":"Djaoud Z, Parham P. HLAs, TCRs, and KIRs, a triumvirate of human cell-mediated immunity. Ann Rev Biochem. 2020;89:717\u201339.","journal-title":"Ann Rev Biochem"},{"issue":"2","key":"548_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","volume":"25","author":"N Anfossi","year":"2006","unstructured":"Anfossi N, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25(2):331\u201342.","journal-title":"Immunity"},{"issue":"1","key":"548_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1034\/j.1600-065X.2002.19004.x","volume":"190","author":"KC Hsu","year":"2002","unstructured":"Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev. 2002;190(1):40\u201352.","journal-title":"Immunol Rev"},{"issue":"5","key":"548_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s00251-002-0476-2","volume":"54","author":"N G\u00f3mez-Lozano","year":"2002","unstructured":"G\u00f3mez-Lozano N, Gardiner CM, Parham P, Vilches C. Some human KIR haplotypes contain two KIR2DL5 genes: KIR2DL5A and KIR2DL5B. Immunogenetics. 2002;54(5):314\u20139.","journal-title":"Immunogenetics"},{"key":"548_CR19","doi-asserted-by":"crossref","unstructured":"Gao F, Ye Y, Gao Y, Huang H, Zhao Y. Influence of KIR and NK cell reconstitution in the outcomes of hematopoietic stem cell transplantation. Front Immunol. 2020:2022.","DOI":"10.3389\/fimmu.2020.02022"},{"issue":"6","key":"548_CR20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1074-7613(00)80394-5","volume":"7","author":"M Uhrberg","year":"1997","unstructured":"Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier LL, Parham P. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7(6):753\u201363.","journal-title":"Immunity"},{"key":"548_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev.genom.7.080505.115726","volume":"7","author":"AA Bashirova","year":"2006","unstructured":"Bashirova AA, Martin MP, McVicar DW, Carrington M. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet. 2006;7:277\u2013300.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"4","key":"548_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1034\/j.1399-0039.2001.057004358.x","volume":"57","author":"M Toneva","year":"2001","unstructured":"Toneva M, Lepage V, Lafay G, Dulphy N, Busson M, Lester S, Vu-Trien A, Michaylova A, Naumova E, McCluskey J, Charron D. Genomic diversity of natural killer cell receptor genes in three populations. Tissue Antigens. 2001;57(4):358\u201362.","journal-title":"Tissue Antigens"},{"key":"548_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1034\/j.1600-065X.2002.19004.x","volume":"190","author":"KC Hsu","year":"2002","unstructured":"Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: geneorder, haplotypes and allelic polymorphism. Immunol Rev. 2002;190:40\u201352. https:\/\/doi.org\/10.1034\/j.1600-065X.2002.19004.x.","journal-title":"Immunol Rev"},{"key":"548_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri3370","volume":"13","author":"P Parham","year":"2013","unstructured":"Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol. 2013;13:133\u201344. https:\/\/doi.org\/10.1038\/nri3370.","journal-title":"Nat Rev Immunol"},{"key":"548_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/imr.12316","volume":"267","author":"AR Manser","year":"2015","unstructured":"Manser AR, Weinhold S, Uhrberg M. Human KIR repertoires: shaped by genetic diversity and evolution. Immunol Rev. 2015;267:178\u201396. https:\/\/doi.org\/10.1111\/imr.12316.","journal-title":"Immunol Rev"},{"key":"548_CR26","doi-asserted-by":"crossref","unstructured":"Ingrassia F, Cappuzzo V, Bavetta R, Mistretta S, Vega MI, Affaticati PB, Blando M, Bruno F, Collura E, Regina G, Randazzo V. Impact of the Donor KIR Genotype on the Clinical Outcome of Hematopoietic Stem Cell Unrelated Transplants: A Single Center Experience. InStem Cells in Clinical Practice and Tissue Engineering 2018 May 2. IntechOpen.","DOI":"10.5772\/67047"},{"issue":"20","key":"548_CR27","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1182\/blood-2014-09-599993","volume":"125","author":"A Mancusi","year":"2015","unstructured":"Mancusi A, Ruggeri L, Urbani E, Pierini A, Massei MS, Carotti A, Terenzi A, Falzetti F, Tosti A, Topini F, Bozza S. Haploidentical hematopoietic transplantation from KIR\/HLA\u2013mismatched donors with activating KIRs reduces nonrelapse mortality. Blood. 2015;125(20):3173\u201382.","journal-title":"Blood"},{"issue":"2","key":"548_CR28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1046\/j.1365-2141.1996.4941035.x","volume":"93","author":"B Glass","year":"1996","unstructured":"Glass B, Uharek L, Zeis M, Loeffler H, Mueller-Ruchholtz W, Gassmann W. Graft-versus-leukemia activity can be predicted by natural cytotoxicity against leukemia cells. Br J Haematol. 1996;93(2):412\u201320.","journal-title":"Br J Haematol"},{"issue":"12","key":"548_CR29","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1182\/blood-2004-12-4825","volume":"105","author":"KC Hsu","year":"2005","unstructured":"Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O\u2019Reilly RJ, Horowitz MM, Dupont B. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105(12):4878\u201384.","journal-title":"Blood"},{"issue":"4","key":"548_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","volume":"12","author":"B George","year":"2010","unstructured":"George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transplant Infect Dis. 2010;12(4):322\u20139. https:\/\/doi.org\/10.1111\/j.1399-3062.2010.00504.x.","journal-title":"Transplant Infect Dis"},{"issue":"14","key":"548_CR31","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1182\/blood-2010-05-283051","volume":"116","author":"S Cooley","year":"2010","unstructured":"Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411\u20139.","journal-title":"Blood"},{"issue":"1","key":"548_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1365-2141.2011.08823.x","volume":"155","author":"W Leung","year":"2011","unstructured":"Leung W. Use of NK cell activity in cure by transplant. Br J Haematol. 2011;155(1):14\u201329.","journal-title":"Br J Haematol"},{"key":"548_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.humimm.2014.08.057","volume":"75","author":"EV Turner","year":"2014","unstructured":"Turner EV, Leung WH. OR54: EFFECTS OF KIR 3DL1 AND HLA-Bw4 MISCLASSIFICATION ON DONOR SELECTION FOR NATURAL KILLER CELL THERAPY. Hum Immunol. 2014;75:47.","journal-title":"Hum Immunol"},{"key":"548_CR34","doi-asserted-by":"crossref","unstructured":"D'Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Elsevier; 2017. p. 1417\u201321.","DOI":"10.1016\/j.bbmt.2017.05.035"},{"issue":"8","key":"548_CR35","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang M-J, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033\u201340.","journal-title":"Blood"},{"issue":"7","key":"548_CR36","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","volume":"127","author":"AS Kanate","year":"2016","unstructured":"Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938\u201347.","journal-title":"Blood"},{"issue":"19","key":"548_CR37","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","volume":"125","author":"SR McCurdy","year":"2015","unstructured":"McCurdy SR, Kanakry JA, Showel MM, Tsai H-L, Bola\u00f1os-Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024\u201331.","journal-title":"Blood"},{"key":"548_CR38","doi-asserted-by":"crossref","unstructured":"Robinson TM, O\u2019Donnell PV, Fuchs EJ, Luznik L, editors. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Seminars in hematology; 2016: Elsevier.","DOI":"10.1053\/j.seminhematol.2016.01.005"},{"issue":"4","key":"548_CR39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","volume":"16","author":"YL Kasamon","year":"2010","unstructured":"Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai H-L, Bola\u00f1os-Meade J, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16(4):482\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"548_CR40","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1182\/bloodadvances.2017006429","volume":"1","author":"F Lorentino","year":"2017","unstructured":"Lorentino F, Labopin M, Fleischhauer K, Ciceri F, Mueller CR, Ruggeri A, et al. The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Adv. 2017;1(11):669\u201380.","journal-title":"Blood Adv"},{"issue":"6","key":"548_CR41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","volume":"124","author":"Y Wang","year":"2014","unstructured":"Wang Y, Chang Y-J, Xu L-P, Liu K-Y, Liu D-H, Zhang X-H, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124(6):843\u201350.","journal-title":"Blood"},{"issue":"1","key":"548_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bbmt.2017.10.002","volume":"24","author":"AM Raiola","year":"2018","unstructured":"Raiola AM, Risitano A, Sacchi N, Giannoni L, Signori A, Aquino S, et al. Impact of HLA disparity in haploidentical bone marrow transplantation followed by high-dose cyclophosphamide. Biol Blood Marrow Transplant. 2018;24(1):119\u201326.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"548_CR43","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.bbmt.2015.09.007","volume":"22","author":"X Bao","year":"2016","unstructured":"Bao X, Wang M, Zhou H, Zhang H, Wu X, Yuan X, et al. Donor killer immunoglobulin-like receptor profile Bx1 imparts a negative effect and centromeric B-specific gene motifs render a positive effect on standard-risk acute myeloid leukemia\/myelodysplastic syndrome patient survival after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(2):232\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"548_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","volume":"131","author":"A Russo","year":"2018","unstructured":"Russo A, Oliveira G, Berglund S, Greco R, Gambacorta V, Cieri N, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131(2):247\u201362.","journal-title":"Blood"},{"key":"548_CR45","doi-asserted-by":"crossref","unstructured":"Roberto A, Di Vito C, Zaghi E, Mazza EMC, Capucetti A, Calvi M, et al. The early expansion of anergic NKG2Apos\/CD56dim\/CD16neg natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation. haematologica. 2018;103(8):1390.","DOI":"10.3324\/haematol.2017.186619"},{"key":"548_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fimmu.2015.00101","volume":"6","author":"TV Brennan","year":"2015","unstructured":"Brennan TV, Rendell VR, Yang Y. Innate immune activation by tissue injury and cell death in the setting of hematopoietic stem cell transplantation. Front Immunol. 2015;6:101.","journal-title":"Front Immunol"},{"issue":"1","key":"548_CR47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296\u2013307.","journal-title":"Blood"},{"issue":"1","key":"548_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/imr.12157","volume":"258","author":"B Foley","year":"2014","unstructured":"Foley B, Felices M, Cichocki F, Cooley S, Verneris MR, Miller JS. The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev. 2014;258(1):45\u201363.","journal-title":"Immunol Rev"},{"issue":"7","key":"548_CR49","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1182\/blood.V95.7.2240","volume":"95","author":"AE Broers","year":"2000","unstructured":"Broers AE, van der Holt R, van Esser JW, Gratama J-W, Henzen-Logmans S, Kuenen-Boumeester V, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell\u2013depleted stem cell transplantation. Blood. 2000;95(7):2240\u20135.","journal-title":"Blood"},{"issue":"4","key":"548_CR50","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","volume":"12","author":"B George","year":"2010","unstructured":"George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis. 2010;12(4):322\u20139.","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"548_CR51","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1046\/j.1365-2141.2001.02849.x","volume":"113","author":"N Kr\u00f6ger","year":"2001","unstructured":"Kr\u00f6ger N, Zabelina T, Kr\u00fcger W, Renges H, Stute N, Schrum J, et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol. 2001;113(4):1060\u201371.","journal-title":"Br J Haematol"},{"key":"548_CR52","doi-asserted-by":"crossref","unstructured":"Itzykson R, Robin M, Moins-Teisserenc H, Delord M, Busson M, Xhaard A, et al. Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation. haematologica. 2015;100(1):114.","DOI":"10.3324\/haematol.2014.113415"},{"issue":"25","key":"548_CR53","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1182\/blood-2015-03-631853","volume":"125","author":"Y Suessmuth","year":"2015","unstructured":"Suessmuth Y, Mukherjee R, Watkins B, Koura DT, Finstermeier K, Desmarais C, et al. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCR\u03b2 repertoire. Blood. 2015;125(25):3835\u201350.","journal-title":"Blood"},{"issue":"9","key":"548_CR54","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.bbmt.2016.05.020","volume":"22","author":"A Kalra","year":"2016","unstructured":"Kalra A, Williamson T, Daly A, Savoie ML, Stewart DA, Khan F, et al. Impact of donor and recipient cytomegalovirus serostatus on outcomes of antithymocyte globulin\u2013conditioned hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(9):1654\u201363.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"548_CR55","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/cid\/ciu364","volume":"59","author":"P Ljungman","year":"2014","unstructured":"Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis. 2014;59(4):473\u201381.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"548_CR56","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.bbmt.2010.07.020","volume":"17","author":"A Ugarte-Torres","year":"2011","unstructured":"Ugarte-Torres A, Hoegh-Petersen M, Liu Y, Zhou F, Williamson TS, Quinlan D, et al. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2011;17(4):574\u201385.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"548_CR57","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1182\/blood-2009-02-203307","volume":"113","author":"W Zhou","year":"2009","unstructured":"Zhou W, Longmate J, Lacey SF, Palmer JM, Gallez-Hawkins G, Thao L, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood. 2009;113(25):6465\u201376.","journal-title":"Blood"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-023-00548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-023-00548-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-023-00548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T17:02:29Z","timestamp":1687280549000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-023-00548-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["548"],"URL":"https:\/\/doi.org\/10.1186\/s12865-023-00548-1","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"assertion":[{"value":"5 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols were approved by the ethical standards of the Ethic Committee of Research Institute for Oncology, Hematology and Cell Therapy of Tehran University of Medical Sciences (IR.MUI.REC.1400.036), and informed consent was obtained from all individual participants included in the study. In the case of minors, informed consent was obtained from the parents or legal guardians of any participant under the age of 16. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}